Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
110,784,314
-
Total 13F shares
-
73,877,500
-
Share change
-
+24,094,275
-
Total reported value
-
$261,528,744
-
Put/Call ratio
-
58%
-
Price per share
-
$3.54
-
Number of holders
-
134
-
Value change
-
+$85,099,354
-
Number of buys
-
80
-
Number of sells
-
46
Institutional Holders of Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) as of Q1 2025
As of 31 Mar 2025 Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) had 134 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 73,877,500 shares of stock of the company.
Largest 10 holders included PERCEPTIVE ADVISORS LLC, TCG Crossover Management, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., VANGUARD GROUP INC, MILLENNIUM MANAGEMENT LLC, Nantahala Capital Management, LLC, CITADEL ADVISORS LLC, Aberdeen Group plc, Saturn V Capital Management LP, and 683 Capital Management, LLC.
This table shows 135 institutional shareholders of the security as of 31 Mar 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.